5 forms: solution. In force in Georgia: 5 of 5 (veterinary register).
Forms and doses5 of 5 in force in Georgia
The dose from the product's label, by species and weight. Check the label of the pack you use.
Form
Species
Weight
Dose
Frequency
Georgia
Solution · Dog up to 4.99 kg
Dog
up to 4.99 kg
0.1 ml/kg
Dogs under 5 kg: draw 0.1 ml/kg (0.5 mg/kg) aseptically from one 5 mg/ml vial and inject under the skin, once a month. Not under 12 months; not in breeding, pregnant or lactating dogs.
Bedinvetmab 5 mg/ml, solution for injection for dogs (1 ml vial)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dogs under 5 kg: draw 0.1 ml/kg (0.5 mg/kg) aseptically from one 5 mg/ml vial and inject under the skin, once a month. Not under 12 months; not in breeding, pregnant or lactating dogs.
Dog
up to 4.99 kg
Subcutaneous
monthly
EMA SPC 2026
Official product label (SPC), EMA, EU
Approved by the European Medicines Agency (EMA) as part of the product's authorisation. It applies to that product as authorised there.
Librela 5/10/15/20/30 mg solution for injection for dogs - EU product information (SPC and package leaflet)
European Medicines Agency / Union Product Database, 2026
Bedinvetmab 10 mg/ml, solution for injection for dogs (1 ml vial)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Bedinvetmab 15 mg/ml, solution for injection for dogs (1 ml vial)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Two 20 mg vials drawn into the same syringe, a single 2 ml injection under the skin once a month. Not under 12 months; not in breeding, pregnant or lactating dogs.
Dogs 80.1-100 kg: one 20 mg vial plus one 30 mg vial drawn into the same syringe, a single 2 ml injection under the skin once a month. Not under 12 months; not in breeding, pregnant or lactating dogs.
Bedinvetmab 20 mg/ml, solution for injection for dogs (1 ml vial)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Two 20 mg vials drawn into the same syringe, a single 2 ml injection under the skin once a month. Not under 12 months; not in breeding, pregnant or lactating dogs.
Dog
60–80 kg
Subcutaneous
monthly
EMA SPC 2026
Official product label (SPC), EMA, EU
Approved by the European Medicines Agency (EMA) as part of the product's authorisation. It applies to that product as authorised there.
Librela 5/10/15/20/30 mg solution for injection for dogs - EU product information (SPC and package leaflet)
European Medicines Agency / Union Product Database, 2026
Dogs 80.1-100 kg: one 20 mg vial plus one 30 mg vial drawn into the same syringe, a single 2 ml injection under the skin once a month. Not under 12 months; not in breeding, pregnant or lactating dogs.
Dog
80–100 kg
Subcutaneous
monthly
EMA SPC 2026
Official product label (SPC), EMA, EU
Approved by the European Medicines Agency (EMA) as part of the product's authorisation. It applies to that product as authorised there.
Librela 5/10/15/20/30 mg solution for injection for dogs - EU product information (SPC and package leaflet)
European Medicines Agency / Union Product Database, 2026
Dogs 80.1-100 kg: one 30 mg vial plus one 20 mg vial drawn into the same syringe, a single 2 ml injection under the skin once a month. Not under 12 months; not in breeding, pregnant or lactating dogs.
Two 30 mg vials drawn into the same syringe, a single 2 ml injection under the skin once a month. Not under 12 months; not in breeding, pregnant or lactating dogs.
Bedinvetmab 30 mg/ml, solution for injection for dogs (1 ml vial)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dogs 80.1-100 kg: one 30 mg vial plus one 20 mg vial drawn into the same syringe, a single 2 ml injection under the skin once a month. Not under 12 months; not in breeding, pregnant or lactating dogs.
Dog
80–100 kg
Subcutaneous
monthly
EMA SPC 2026
Official product label (SPC), EMA, EU
Approved by the European Medicines Agency (EMA) as part of the product's authorisation. It applies to that product as authorised there.
Librela 5/10/15/20/30 mg solution for injection for dogs - EU product information (SPC and package leaflet)
European Medicines Agency / Union Product Database, 2026
Two 30 mg vials drawn into the same syringe, a single 2 ml injection under the skin once a month. Not under 12 months; not in breeding, pregnant or lactating dogs.
Dog
100–120 kg
Subcutaneous
monthly
EMA SPC 2026
Official product label (SPC), EMA, EU
Approved by the European Medicines Agency (EMA) as part of the product's authorisation. It applies to that product as authorised there.
Librela 5/10/15/20/30 mg solution for injection for dogs - EU product information (SPC and package leaflet)
European Medicines Agency / Union Product Database, 2026
Do not use in dogs hypersensitive to bedinvetmab or any excipient.
Sources: Librela EU SPC
Critical
Do not use in dogs under 12 months of age.
Sources: Librela EU SPC
Critical
Do not use in pregnant bitches: anti-NGF antibodies were teratogenic and foetotoxic in monkey studies.
Sources: Librela EU SPC
Critical
Do not use in lactating bitches.
Sources: Librela EU SPC
Warning
Do not use in dogs intended for breeding.
Sources: Librela EU SPC
Caution
Use with caution in dogs with a pre-existing seizure disorder.
Sources: Librela EU SPC
Caution
Use with caution in immune-mediated haemolytic anaemia, polyarthritis or thrombocytopenia. New or worse joint swelling or pain after treatment needs investigation and may mean stopping. No safety data on long-term use with NSAIDs.
Sources: Librela EU SPC
Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.
For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.
Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.
The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.
